REG - Oncimmune Hldngs PLC - Grant of Options and PDMR notification

Oncimmune HoldingsAnnouncement

09/06/2020 15:55

RNS Number : 4420P
  
Oncimmune Holdings PLC
  
09 June 2020
  
 

Oncimmune Holdings plc
("Oncimmune" or the "Company")
 
Grant of Options and PDMR notification
 
Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, today announces that, as part of its annual management incentivisation scheme, options ("Options") to subscribe for an aggregate of 324,474 ordinary shares of £0.01 each in the Company ("Ordinary Shares") were granted on 5 June 2020 to each of Adam Hill, Chief Executive Officer, Matthew Hall, Chief Financial Officer, Matthew Luttrell, Chief Commercial Officer, and Tariq Sethi, Chief Scientific Officer as follows:
 



Name


Position


Number of Share Options Awarded


Exercise Price per Ordinary
Share


Total Options held post grant


Total number of Ordinary Shares currently held


% of total issued share capital




Adam Hill


Chief Executive Officer


129,288


£1.195


526,113


40,913


0.06%




Matthew Hall


Chief Financial Officer


134,936


£1.195


295,486


11,935


0.02%




Matthew Luttrell


Chief Commercial Officer


42,677


£1.195


266,361


-


-




Tariq Sethi


Chief Scientific Officer


17,573


£1.195


109,678


-


-



 
The Options have been granted under the 2016 Share Option Plan, have an exercise price of £1.195, being the closing price of Ordinary Shares on  4 June 2020, and vest annually in five equal parts from the date of grant until the fifth anniversary of grant.  
 
This announcement, including the notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
 
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
 



1
 


Details of the person discharging managerial responsibilities / person closely associated
 




a)
 


Name
 
 


1)   Adam Hill
2)   Matthew Hall
3)   Matthew Luttrell
4)   Tariq Sethi




2
 


Reason for the notification
 




a)
 


Position/status
 
 


1)   Chief Executive Officer
2)   Chief Financial Officer
3)   Chief Commercial Officer
4)   Chief Scientific Officer




b)
 


Initial notification /Amendment
 
 


Initial notification




3
 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 




a)
 


Name
 
 


Oncimmune Holdings plc




b)
 


LEI
 
 


213800HCYIWT6YPI1I02 




4
 


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
 
 




a)
 


Description of the financial instrument, type of instrument


Ordinary Shares of £0.01 each
 














Identification code


ISIN: GB00BYQ94H38














b)
 


Nature of the transaction
 
 


Grant of options




c)
 


Price(s) and volume(s)




























Price(s)


Volume(s)
















1) £1.195


129,288
















2) £1.195


134,936
















3) £1.195 


42,677
















4) £1.195


17,573






























d)
 


Aggregated information


















- Aggregated volume


As above      














- Price


















e)
 


Date of the transaction
 
 


5 June 2020




f)
 


Place of the transaction
 
 


Outside a trading venue



 
For further information:
Oncimmune Holdings plc
Ron Kirschner, General Counsel & Company Secretary
contact@oncimmune.co.uk
 
 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
DSHUPUGAQUPUGCB